These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. Soundararajan R; Aparicio AM; Logothetis CJ; Mani SA; Maity SN Front Oncol; 2018; 8():69. PubMed ID: 29600194 [TBL] [Abstract][Full Text] [Related]
28. Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer. Turina CB; Coleman DJ; Thomas GV; Fung AW; Alumkal JJ Cureus; 2019 Jul; 11(7):e5197. PubMed ID: 31565603 [TBL] [Abstract][Full Text] [Related]
29. Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression. Wang Z; Zhao Y; An Z; Li W Front Oncol; 2019; 9():1491. PubMed ID: 32039001 [TBL] [Abstract][Full Text] [Related]
30. Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma. Chedgy EC; Vandekerkhove G; Herberts C; Annala M; Donoghue AJ; Sigouros M; Ritch E; Struss W; Konomura S; Liew J; Parimi S; Vergidis J; Hurtado-Coll A; Sboner A; Fazli L; Beltran H; Chi KN; Wyatt AW J Pathol; 2018 Oct; 246(2):244-253. PubMed ID: 30015382 [TBL] [Abstract][Full Text] [Related]
31. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. Nyquist MD; Corella A; Coleman I; De Sarkar N; Kaipainen A; Ha G; Gulati R; Ang L; Chatterjee P; Lucas J; Pritchard C; Risbridger G; Isaacs J; Montgomery B; Morrissey C; Corey E; Nelson PS Cell Rep; 2020 May; 31(8):107669. PubMed ID: 32460015 [TBL] [Abstract][Full Text] [Related]
32. Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4. Coleman DJ; Sampson DA; Sehrawat A; Kumaraswamy A; Sun D; Wang Y; Schwartzman J; Urrutia J; Lee AR; Coleman IM; Nelson PS; Dong X; Morrissey C; Corey E; Xia Z; Yates JA; Alumkal JJ Neoplasia; 2020 Jun; 22(6):253-262. PubMed ID: 32403054 [TBL] [Abstract][Full Text] [Related]
33. Targeting Wnt/EZH2/microRNA-708 signaling pathway inhibits neuroendocrine differentiation in prostate cancer. Shan J; Al-Muftah MA; Al-Kowari MK; Abuaqel SWJ; Al-Rumaihi K; Al-Bozom I; Li P; Chouchane L Cell Death Discov; 2019; 5():139. PubMed ID: 31583122 [TBL] [Abstract][Full Text] [Related]
34. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network. Lee AR; Gan Y; Tang Y; Dong X EBioMedicine; 2018 Sep; 35():167-177. PubMed ID: 30100395 [TBL] [Abstract][Full Text] [Related]
35. Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2. Liu Q; Pang J; Wang LA; Huang Z; Xu J; Yang X; Xie Q; Huang Y; Tang T; Tong D; Liu G; Wang L; Zhang D; Ma Q; Xiao H; Lan W; Qin J; Jiang J J Pathol; 2021 Jan; 253(1):106-118. PubMed ID: 33009820 [TBL] [Abstract][Full Text] [Related]
36. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708 [TBL] [Abstract][Full Text] [Related]
37. Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway. Ji Y; Liu B; Chen L; Li A; Shen K; Su R; Zhang W; Zhu Y; Wang Q; Xue W Cell Oncol (Dordr); 2023 Oct; 46(5):1445-1456. PubMed ID: 37120492 [TBL] [Abstract][Full Text] [Related]
38. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. Beltran H; Romanel A; Conteduca V; Casiraghi N; Sigouros M; Franceschini GM; Orlando F; Fedrizzi T; Ku SY; Dann E; Alonso A; Mosquera JM; Sboner A; Xiang J; Elemento O; Nanus DM; Tagawa ST; Benelli M; Demichelis F J Clin Invest; 2020 Apr; 130(4):1653-1668. PubMed ID: 32091413 [TBL] [Abstract][Full Text] [Related]
39. High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer. Chen L; Ji Y; Li A; Liu B; Shen K; Su R; Ma Z; Zhang W; Wang Q; Zhu Y; Xue W Front Oncol; 2023; 13():1085569. PubMed ID: 36994207 [TBL] [Abstract][Full Text] [Related]
40. ONECUT2 is a driver of neuroendocrine prostate cancer. Guo H; Ci X; Ahmed M; Hua JT; Soares F; Lin D; Puca L; Vosoughi A; Xue H; Li E; Su P; Chen S; Nguyen T; Liang Y; Zhang Y; Xu X; Xu J; Sheahan AV; Ba-Alawi W; Zhang S; Mahamud O; Vellanki RN; Gleave M; Bristow RG; Haibe-Kains B; Poirier JT; Rudin CM; Tsao MS; Wouters BG; Fazli L; Feng FY; Ellis L; van der Kwast T; Berlin A; Koritzinsky M; Boutros PC; Zoubeidi A; Beltran H; Wang Y; He HH Nat Commun; 2019 Jan; 10(1):278. PubMed ID: 30655535 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]